ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.1130G>T (p.Cys377Phe)

dbSNP: rs879254801
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Cardiovascular Research Group, Instituto Nacional de Saude Doutor Ricardo Jorge RCV000505209 SCV000599362 likely pathogenic Hypercholesterolemia, familial, 1 2016-03-01 criteria provided, single submitter curation
Laboratory of molecular diagnosis of dyslipidemias, Università egli studi di Napoli Federico II RCV000505209 SCV001653623 likely pathogenic Hypercholesterolemia, familial, 1 2021-05-24 criteria provided, single submitter clinical testing
Ambry Genetics RCV002323869 SCV002610167 pathogenic Cardiovascular phenotype 2018-07-20 criteria provided, single submitter clinical testing The p.C377F pathogenic mutation (also known as c.1130G>T), located in coding exon 8 of the LDLR gene, results from a G to T substitution at nucleotide position 1130. The cysteine at codon 377 is replaced by phenylalanine, an amino acid with highly dissimilar properties, and is located in the EGF-like 2 domain. Pathogenic LDLR alterations that result in the substitution or generation of cysteine residues within the cysteine-rich LDLR class A repeats and EGF-like domains are common in familial hypercholesterolemia (FH) (Villéger L. Hum Mutat. 2002;20(2):81-7). This variant was reported in an individual with FH, and functional studies demonstrated a significant reduction in LDLR activity (Romano M et al. J. Lipid Res., 2011 Nov;52:2095-100). Internal structural analysis indicates this alteration eliminates a disulfide bond critical for the structural integrity of EGF-like 2 domain (Ambry internal data). Alternate amino acid substitutions at this position, including p.C377S (c.1130G>C), p.C377G (c.1129T>G) and p.C377Y (c.1130G>A) have also been reported in individuals with FH (Ekström U et al. Eur. J. Clin. Invest. 1998 Sep;28:740-7; Bertolini S et al. Atherosclerosis. 2013 Apr;227: 342-8; Wu WF et al. PLoS ONE 2014 Apr; 9:e94697). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.